Effect of Zhenqi fuzheng capsule combined with adefovir dipivoxil on hepatitis B virus replication and cell immune function in patients with chronic hepatitis

LIU Jun¹, ZHOU Rong-zhong²
(1. Emergency Department, Hubei Provincial Center for Disease Control and Prevention, Zaoyang 441200, China; 2. Emergency Department, First People's Hospital, Zaoyang 441200, China)

[Foundation Project]: It is supported by Health Department Planning Project of Hubei (2010-17).

[Author]: LIU Jun (1971-), Female, Zaoyang Hubei, Attending Physician, M. B., Tel: 13871721610, E-mail: liujunjk@163.com.

Received: 2014-10-27 Revised: 2014-11-13

JHMC, 2015; 21(2): 181-183

View from specialist: It is creative, and of certain scientific and educational value.

[ABSTRACT] Objective: To study the effect of Zhenqi fuzheng capsule combined with adefovir dipivoxil on hepatitis B virus replication and cell immune function in patients with chronic hepatitis B. Methods: A total of 100 cases patients with chronic hepatitis B in our hospital from 2012 January to 2014 April were enrolled and randomly divided into observation group and control group. Observation group received Zhenqi fuzheng capsule combined with adefovir dipivoxil treatment, control group received adefovir dipivoxil treatment. Then hepatitis B virus replication, liver fibrosis indexes and cell immune function were compared. Results: HBV-DNA copy number and drug-resistant rate of observation group were significantly lower than that of control group[(3.21±0.57 ×10⁴ vs. (8.19±1.17) ×10⁴, 4.62% vs. 15.38%)]. HBV-DNA negative rate were significantly higher than control group(93.85% vs. 73.85%). HA, LN, IV C, P III NP levels of observation group were significantly lower than those of control group (125.21±27.32 vs. 160.65±25.78, 105.65±16.52 vs. 138.42±23.32, 124.20±25.42 vs. 140.53±25.52, 162.28±37.25 vs. 187.17±37.58). CD4⁺, CD4/CD8, CD16/65⁺ NK of observation group were significantly higher than those of control group (43.62±5.65 vs. 32.67±4.51, 2.12±0.34 vs. 1.32±0.24, 22.56±4.28 vs. 13.45±2.12); CD8⁺ T cells was significantly lower than control group(23.27±2.90 vs. 29.41±3.75). Conclusions: Zhenqi fuzheng capsule combined with adefovir dipivoxil treatment is helpful to inhibit the replication of HBV, relieve liver fibrosis, improve cell immune function, and improve therapeutic effect.

[KEY WORDS] hepatitis B; Zhenqi fuzheng capsule; Adefovir dipivoxil; Cellular immunity